Identification of Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach

09 April 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

In this work, Computer-aided drug design method has been implemented to quickly identify promising drug repurposing candidates against COVID-19. The world is facing an epidemic and in absence of vaccine or any effective treatment, it has created a sense of urgency for novel drug discovery approaches. We have made an immediate effort by performing virtual screening of clinically approved drugs or molecules under clinical trials against COVID-19 to identify potential drug molecules.

With given knowledge of this system, N3 and 13B compounds have shown inhibitory effect against COVD-19. Both the compounds were considered as control to filter out the screened molecules. Overall, we have identified six potential compounds, Leupeptin Hemisulphate, Pepstatin A, Nelfinavir , Birinapant, Lypression and Octeotide which have shown the docking energy > -8 kcal/mol and MMGBSA > -90 kcal/mol. The binding pattern of these compounds suggests that they interact with key hot-spot residues. Also, the pharmacokinetic annotations and their biological activity have indicated that they possess drug-like properties and pave their way for in vitro studies

The findings of this work will be significant for structure and pharmacophore-based designing

Keywords

virtual screening
COVID_19
SARS-CoV-2
Molecular docking analysis
Binding free energy

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.